What is the current stock price of Immunovant, Inc. (IMVT)?

As of the latest market data, Immunovant, Inc. (IMVT) is trading at $33.41. The stock has seen a loss of -1.24% today.

Does Immunovant, Inc. (IMVT) pay a dividend?

Based on current data, Immunovant, Inc. does not have a confirmed active dividend policy.

What is the market cap of Immunovant, Inc.?

The current market capitalization of Immunovant, Inc. (IMVT) is approximately unavailable.

IMVT

Immunovant, Inc.·Healthcare

33.41

1.242%(−0.42)

Close Price

35.78

7.094%(+2.37)

Pre-Market

Last Updated: — ET

52W L: $14.0952W H: $36.28

IMVT NEWS

seekingalpha.com

3d ago

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential

Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.

seekingalpha.com

6d ago

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy

Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.

benzinga.com

6d ago

These Analysts Increase Their Forecasts On Immunovant After Q4 Results

Immunovant Inc (NASDAQ:IMVT) on Wednesday posted a wider fourth‑quarter loss than analysts expected.

zacks.com

6d ago

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.

benzinga.com

May 20

Immunovant Stock Surges Despite Disappointing Earnings Miss

Immunovant Inc (NASDAQ:IMVT) shares are trading higher on Wednesday even though the company posted a wider fourth‑quarter loss than analysts expected.

marketbeat.com

May 20

Immunovant Q4 Earnings Call Highlights

Roivant executives used the company's fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna.

Company Profile

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.

Sector

Healthcare

Industry

Biotechnology

Employees

362

IPO Date

2019-06-21

Beta

0.70

Websiteimmunovant.com↗